CommercialCoverageMedium impact
08.00.85r, Tocilizumab and Related Biosimilars for Intravenous Infusion
Independence Blue Cross·Rheumatology, Oncology, Hematology·Pharmacy
Effective date
Oct 1, 2025
We identified it
Jun 19, 2026
Summary
Independence Blue Cross updated their policy for Tocilizumab and related biosimilars for intravenous infusion, effective October 1, 2025. This is a pharmacy policy change that may affect coverage criteria, prior authorization requirements, or billing procedures for this medication used primarily in rheumatology and oncology.
Action Required
By October 1, 2025: Review the complete policy at the provided URL to identify specific changes to Tocilizumab billing requirements. Update prior authorization procedures, coverage criteria, and billing workflows as specified in the full policy. Notify providers who administer Tocilizumab infusions of any new requirements.